Fig. 3From: Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRIOAR DVH for Patient 1, isoeffective Plans A and B. Dose distributions of the plans were scaled to achieve equivalent tumour control (<TCP > =0.95). Results for all patients are available in the supplementary documentBack to article page